AmCad BioMed (4188) reported revenue of NT$2.1 million for Oct 2026, -16.6% year on year and -6.3% from the previous month. Revenue for Jan–Oct 2026 was NT$23.2 million (-16.8% year on year).
In Oct 2026, it ranked No. 142 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$2.1 million | -16.6% | -6.3% |
| Sep 2026 | NT$2.3 million | -62.2% | -5.9% |
| Aug 2026 | NT$2.4 million | +2.9% | -28.1% |
| Jul 2026 | NT$3.3 million | +56.5% | +80.2% |
| Jun 2026 | NT$1.9 million | -38.3% | -15.2% |
| May 2026 | NT$2.2 million | -8.7% | -18.7% |
| Apr 2026 | NT$2.7 million | -3.0% | +39.8% |
| Mar 2026 | NT$1.9 million | -13.1% | +23.7% |
| Feb 2026 | NT$1.6 million | -31.6% | -46.7% |
| Jan 2026 | NT$2.9 million | +26.5% | +138.1% |
| Dec 2025 | NT$1.2 million | -84.3% | -6.3% |
| Nov 2025 | NT$1.3 million | -81.1% | -48.5% |
| Oct 2025 | NT$2.5 million | -25.6% | -57.5% |
| Sep 2025 | NT$6 million | +73.9% | +156.0% |
| Aug 2025 | NT$2.3 million | -7.5% | +9.4% |
| Jul 2025 | NT$2.1 million | -53.3% | -28.9% |
| Jun 2025 | NT$3 million | -50.1% | +25.4% |
| May 2025 | NT$2.4 million | -67.4% | -13.6% |
| Apr 2025 | NT$2.8 million | -8.3% | +25.3% |
| Mar 2025 | NT$2.2 million | -1.6% | -2.6% |
| Feb 2025 | NT$2.3 million | -35.0% | -1.6% |
| Jan 2025 | NT$2.3 million | -1.7% | -70.5% |
| Dec 2024 | NT$7.8 million | -23.7% | +13.1% |
| Nov 2024 | NT$6.9 million | +36.9% | +103.0% |
| Oct 2024 | NT$3.4 million | -58.0% | -0.8% |
Jan–Oct 2026 cumulative: NT$23.2 million (-16.8% YoY)
Other Biotech & Medical companies
Compare with peers: AmCad BioMed vs PEC / AmCad BioMed vs Lotus Pharm / AmCad BioMed vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16